Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 236

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 236
---
 A Preferred Stock sold to certain investors pursuant to the First and Second Securities Purchase
                                            Agreement and conversion of the underlying shares of Series A Preferred Stock into Common
                                            Stock and (xi) 4,425 shares of Common Stock issuable upon the exercise of Private Placement
                                            Warrants to purchase shares of our Common Stock, at an exercise price of $1,150.00 per share,
                                            that were originally sold in a private placement concurrently with the Initial Public Offering;
                                            and (2) the issuance by us of up to 87,500 shares of Common Stock issuable upon the exercise
                                            of public warrants to purchase shares of our Common Stock, at an exercise price of $1,150.00
                                            per share, that were originally issued in the Initial Public Offering;

●a registration statement with the SEC for purposes of registering of
the resale from time to time of up to 6,385,638 shares of Common Stock, which consists of (i) 576,710 shares of Common Stock issuable
upon the conversion of shares of our Series A Preferred Stock purchased by certain investors pursuant to the First Securities Purchase
Agreement; (ii) 91,829 shares of Common Stock issuable upon the conversion of shares of our Series B Preferred Stock purchased by certain
investors pursuant to the Second Securities Purchase Agreement; (iii) 707,394 shares of Common Stock issued upon the conversion of shares
of our Series A Preferred Stock and Series B Preferred Stock; (iv) 4,366,837 shares of Common Stock issuable upon the conversion of 300%
of the number of outstanding shares of our Series C Preferred Stock purchased by certain investors pursuant to the Third Securities Purchase
Agreement; (v) 2,500 shares of Common Stock issued to a stockholder in a reallocation of shares in connection with the consummation of
the Business Combination; (vi) 81,752 shares of Common Stock issuable upon the exercise of warrants to purchase shares of our Common Stock,
at an exercise price of $9.80 per share, which warrants were sold to certain investors pursuant to the Third Securities Purchase Agreement
(the “Series C Warrants”); and (ii) 558,617 shares of Common Stock issuable upon the conversion of shares of Series A Preferred
Stock resulting from the exercise of outstanding Preferred Warrants; and

●a
                                            registration statement with the SEC for the purposes of registering the primary issuance
                                            by the Company of (i) 300